Literature DB >> 21848901

Characteristics of low-density and high-density lipoprotein subclasses in pediatric renal transplant recipients.

Aleksandra Zeljkovic1, Jelena Vekic, Vesna Spasojevic-Kalimanovska, Zorana Jelic-Ivanovic, Amira Peco-Antic, Mirjana Kostic, Dragan Vasic, Slavica Spasic.   

Abstract

Renal transplant recipients often suffer from dyslipidemia which is one of the principal risk factors for cardiovascular disease. This study sought to determine characteristics of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles and their associations with carotid intima-media thickness (cIMT) in a group of pediatric renal transplant recipients. We also examined the influence of immunosuppressive therapy on measured LDL and HDL particle characteristics. HDL size and subclass distribution were determined using gradient gel electrophoresis, while concentrations of small, dense LDL (sdLDL)-cholesterol (sdLDL-C) and sdLDL-apolipoprotein B (sdLDL-apoB) using heparin-magnesium precipitation method in 21 renal transplant recipients and 32 controls. Renal transplant recipients had less HDL 2b (P < 0.001), but more HDL 3a (P < 0.01) and 3b (P < 0.001) subclasses. They also had increased sdLDL-C (P < 0.01) and sdLDL-apoB (P < 0.05) levels. The proportion of the HDL 3b subclasses was a significant predictor of increased cIMT (P < 0.05). Patients treated with cyclosporine had significantly higher sdLDL-C and sdLDL-apoB concentrations (P < 0.05) when compared with those on tacrolimus therapy. Pediatric renal transplant recipients have impaired distribution of HDL and LDL particles. Changes in the proportion of small-sized HDL particles are significantly associated with cIMT. Advanced lipid testing might be useful in evaluating the effects of immunosuppressive therapy.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848901     DOI: 10.1111/j.1432-2277.2011.01313.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

Review 1.  Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Arrigo F G Cicero; Andrej Janez; Anca Pantea Stoian; Alper Sonmez; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-02-16       Impact factor: 2.430

Review 2.  Long-term effects of paediatric kidney transplantation.

Authors:  Christer Holmberg; Hannu Jalanko
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

3.  Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults.

Authors:  Andrew J Clifford; Gonzalo Rincon; Janel E Owens; Juan F Medrano; Alanna J Moshfegh; David J Baer; Janet A Novotny
Journal:  Lipids Health Dis       Date:  2013-05-08       Impact factor: 3.876

4.  Association of Myeloperoxidase and the Atherogenic Index of Plasma in Children with End-Stage Renal Disease.

Authors:  Danijela Ristovski-Kornic; Aleksandra Stefanović; Jelena Kotur-Stevuljević; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Jelena Vekić; Milica Miljković; Dušan Paripović; Amira Peco-Antić; Zorana Jelić-Ivanović
Journal:  J Med Biochem       Date:  2017-01-25       Impact factor: 3.402

5.  Alterations of HDL Particles in Children with End-stage Renal Disease.

Authors:  Aleksandra Stefanović; Danijela Ristovski-Kornic; Jelena Kotur-Stevuljević; Vesna Spasojević-Kalimanovska; Jelena Vekić; Milica Miljković; Dusan Paripović; Amira Peco-Antic; Zorana Jelić-Ivanović; Aleksandra Zeljković
Journal:  J Med Biochem       Date:  2017-10-28       Impact factor: 3.402

6.  Use of Statins in Kidney Transplant Recipients in Norway.

Authors:  Marit Rønning; Vidar Hjellvik; Solveig Sakshaug; Hege Salvesen Blix; Karsten Midtvedt; Anna Varberg Reisæter; Hallvard Holdaas; Anders Åsberg
Journal:  Int J Environ Res Public Health       Date:  2022-01-26       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.